Form 4: CervoMed Director Jeffrey Poulton Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Jeffrey V. Poulton was granted 8,150 stock options as part of CervoMed Inc.'s non-employee director compensation policy.
Summary
- Jeffrey V. Poulton, a director at CervoMed Inc., was granted 8,150 stock options on June 8, 2026.
- The grant was issued in connection with his election to the board of directors at the 2026 Annual Meeting of Stockholders.
- The options have an exercise price of $2.91 per share.
- The options vest monthly over a one-year period, starting June 30, 2026, contingent on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Standardized compensation practice following the 2025 Equity Incentive Plan.
Negatives
- Minor dilution of existing shares upon future exercise of options.
Risks
- Market price volatility could impact the value of the options.
- Vesting is subject to continued service on the board.
Future Outlook
The options vest in 1/12th increments monthly over one year, provided the director remains in service.
Management Comments
- The grant is in accordance with the terms of the Issuer's non-employee director compensation policy.
Industry Context
StockSavvy.ai notes that equity grants for non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term shareholder value.
Comparison to Industry Standards
- The use of a 2025 Equity Incentive Plan is consistent with current biotech industry standards for board compensation.
- Monthly vesting over one year is a standard retention mechanism for board members.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of stock options to a director following election at the 2026 Annual Meeting. | 06/08/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Shareholders: Minor dilution impact.
- Director: Increased equity stake in the company.
Next Steps
- Monthly vesting of options beginning June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/08/2026 | Date of grant and earliest transaction. |
| 06/10/2026 | Date of filing. |
| 06/30/2026 | Beginning of monthly vesting period. |
| 06/08/2036 | Expiration date of the stock options. |
Keywords
CervoMed, CRVO, Form 4, Director Compensation, Stock Options, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.